TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05447832

Intervention type: DEVICE
Intervention: Lung function monitoring equipment at home - 2 weeks
Description: The parent/carer setup the lung function monitoring equipment (Ventica®), and placed the WheezeScan® device on the child's chest at home before the child goes to sleep. This is performed once daily for 2 weeks.

Intervention type: DEVICE
Intervention: Lung function monitoring equipment at home - 4 months
Description: The parent/carer setup the lung function monitoring equipment (Ventica®), and placed the WheezeScan® device on the child's chest at home before the child goes to sleep. This is performed once weekly for 4 months.
Study: NCT05545969

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab is a potent and highly selective humanized monoclonal antibody (mAb) of the IgG4/kappa isotype designed to directly block the interaction between PD-1 and its ligands, PD-L1 and PD-L2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Lenvatinib is an oral potent multiple RTK inhibitor that selectively inhibits VEGF receptors, VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4), fibroblast growth factor receptor (FGFR1-4), platelet derived growth factor (PDGFRα), stem cell factor receptor (KIT), and rearranged during transfection (RET)
Study: NCT06531135

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: T-CBSM
Description: A 10-week remotely-delivered group, lasting about 120 minutes each session.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Support group
Description: Participants will receive weekly supportive-expressive group intervention for two hours per week for five weeks total.
Study: NCT05416775

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-8068；Adebrelimab
Description: SHR-8068: Sterile Injection, 50mg/10mL, Intravenous Infusion Adebrelimab: injection, 600mg/12mL, intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-8068；adebrelimab and platinum-based chemotherapy
Description: SHR-8068: Intravenous Infusion Adebrelimab: injection, intravenous infusion Pemetrexed disodium for injection: , intravenous drip Paclitaxel for injection (albumin-bound): intravenous drip Paclitaxel injection: intravenous drip Carboplatin injection: intravenous drip Cisplatin injection: intravenous drip

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adebrelimab；platinum-based chemotherapy
Description: Adebrelimab: intravenous infusion Pemetrexed disodium for injection: intravenous drip Paclitaxel for injection (albumin-bound): intravenous drip Paclitaxel injection: intravenous drip Carboplatin injection: intravenous drip Cisplatin injection: intravenous drip
Study: NCT04882163

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafasitamab
Description: Tafasitamab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafasitamab
Description: Tafasitamab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin
Study: NCT05221203

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TR-30
Description: Bodyweight training exercises will be performed for 30 seconds and the training volume will be consisted of 1 repetition.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TR-45
Description: Bodyweight training exercises will be performed for 45 seconds and the training volume will be consisted of 1 repetition.
Study: NCT05386186

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glimepiride
Description: Initiate glimepiride 1-4mg once daily as an add-on therapy to metformin and adjust the glimepiride dosage to 1-6 mg once daily in the first 12 weeks according to the diabetes management guideline recommended by the Chinese Diabetes Society.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin
Description: Add sitagliptin 100mg once daily in all patients randomized to this arm.
Study: NCT05103813

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beraprost Sodium Tablets
Description: Protective effect of Beraprost Sodium Tablets on coronary microcirculation function and ventricular remodeling after reperfusion therapy for acute ST segment elevation myocardial infarction
Study: NCT04882163

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Bendamustine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide
Study: NCT04678440

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]F-AraG Imaging
Description: Total body PET imaging using \[18F\]F-AraG

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]F-AraG Imaging
Description: Total body PET imaging using \[18F\]F-AraG
Study: NCT06560645

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRT7732
Description: PRT7732 capsules will be self-administered once daily at the dose-level assigned
Study: NCT06560697

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: SABR VS Intracavitary 3D Brachytherapy
Description: Arm 1 will be the experimental arm and will consist of patients with CC clinical stages IB3-IIIC1 who will be treated with CT/RT with a minimum dose of 45Gy and boost in the case of macroscopic nodes (1.8Gy per fraction from Monday to Friday) with cisplatin and cervical boost with SBRT of 28Gy in 4 fractions administered at least every 40 hours to achieve an EQD210(Gy) at PTV D90% of 83.9Gy. Arm 2 will be the control arm that will consist of patients with CC clinical stages IB3-IIIC1 and will be treated with CT/RT with a minimum dose of 45Gy and boost in the case of macroscopic nodes (1.8Gy per fraction from Monday to Friday) with cisplatin and cervical boost with high-dose-rate 3D brachytherapy with a dose of 28Gy in 4 fractions administered at least every 40 hours to achieve an EQD210(Gy) at point A of 83.9Gy.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SABR VS Intracavitary 3D Brachytherapy
Description: Arm 1 will be the experimental arm and will consist of patients with CC clinical stages IB3-IIIC1 who will be treated with CT/RT with a minimum dose of 45Gy and boost in the case of macroscopic nodes (1.8Gy per fraction from Monday to Friday) with cisplatin and cervical boost with SBRT of 28Gy in 4 fractions administered at least every 40 hours to achieve an EQD210(Gy) at PTV D90% of 83.9Gy. Arm 2 will be the control arm that will consist of patients with CC clinical stages IB3-IIIC1 and will be treated with CT/RT with a minimum dose of 45Gy and boost in the case of macroscopic nodes (1.8Gy per fraction from Monday to Friday) with cisplatin and cervical boost with high-dose-rate 3D brachytherapy with a dose of 28Gy in 4 fractions administered at least every 40 hours to achieve an EQD210(Gy) at point A of 83.9Gy.
Study: NCT04932447

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Strength Training
Description: 30 breaths/ day, 5 days/week for 24 weeks.
Study: NCT05447832

Intervention type: DIAGNOSTIC_TEST
Intervention: Inflammation and remodelling from clinical indicted bronchoscopy
Description: For patients who are undergoing clinically indicated bronchoscopy, consent will be obtained to use any surplus clinical samples for this study. The samples to be collected are broncho-alveolar lavage and endobronchial biopsies. Both of these are taken from the airways during clinical bronchoscopy.
Study: NCT06529705

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EkiYou V2
Description: Use of a mobile application that help users to evaluate their daily bolus and basal insulin needs, and that adjusts at weekly basis their insulin to carb ratios, correction factor and basal dose.
Study: NCT06076044

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: toDCS 2mA 1Hz
Description: The subgroup treated by transcranial oscillatory direct current stimulation of 2mA and 1Hz.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: toDCS 2mA 10Hz
Description: The subgroup treated by transcranial oscillatory direct current stimulation of 2mA and 10Hz.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS 1mA
Description: The subgroup treated by transcranial direct current stimulation of 1mA.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: sham
Description: The subgroup treated by sham stimulation.
Study: NCT04519528

Intervention type: OTHER
Intervention: DENVER scale (under 2 years old) or Pediatric Cerebral Performance Category (PCPC) score (over 2 years old)
Description: The DENVER II is a measure of developmental problems in young children. It was designed to assess child performance on various age-appropriate tasks and compares a given child's performance to the performance of other children the same age. The instrument consists of 125 tasks, which broadly reflect the following areas: personal-social, fine motor-adaptive, language, and gross motor.~The target population corresponds to infants and pre-school age children.~The POPC and PCPC are global scales based on observer impressions. Scores include 1 for good, 2 for mild disability, 3 for moderate disability, 4 for severe disability, and 5 for vegetative state or coma (6 indicates death).

Intervention type: OTHER
Intervention: Pediatric Quality of Life Inventory™ (PedsQL)
Description: The PedsQL questionnaire is a modular approach to measuring health-related quality of life in healthy children and adolescents and those with acute and chronic health conditions. The PedsQL Measurement Model integrates seamlessly both generic core scales and disease-specific modules into one measurement system. Twenty-three items divided into different functional areas are evaluated: physical (8 items), emotional (5 items), social (5 items) and school (5 items over 4 years old; 3 items before 4 y.o).~Child self-report and parent proxy report formats of the questionnaire allows self-assessment of child over 5 years old and parents' evaluations. Items can be reverse and linearly transformed to a 0-100 scale (0=100, 1=75, 2=50, 3=25, 4=0) with higher scores indicating better quality of life.
Study: NCT04954846

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: OMNi-BiOTiC SR-9
Description: The Probiotic contains the following ingredients:~Maize Starch, Maltodextrin, Inulin, Potassium Chloride, Hydrolysed rice protein, Magnesium Sulphate, Fructooligosaccharides, Amylase, Manganese Sulphate~Additionally, the following bacterial strains are included:~Lactobacillus Casei W56, Lactobacillus Acidophilus W22, Lactobacillus Paracasei W20, Bifidobacterium lactis W51, Lactobacillus salivarius W24, Lactococcus lactis W19, Bifidobacterium lactis W52, Lactobacillus plantarum, Bifidobacterium bifidum W23

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The Placebo contains no bacterial strains, only the prebiotic ingredients found in OMNi-BiOTiC SR-9.
Study: NCT06511752

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychosocial educational, support group and implementation of strategies
Description: Psychosocial educational, support group and implementation of strategies
Study: NCT05449392

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neosporin
Description: Neosporin is neomycin, bacitracin and polymyxin B with formulation 3.5mg/400 units/5,000 units. The subject will self-apply a small amount (approximately 0.5 g) of the ointment topically into each nostril (intranasal) twice daily (morning and evening) for seven days. Subjects are to pinch the nose to spread the cream.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vaseline
Description: The subject will self-apply a small amount (approximately 0.5 g) of the ointment topically into each nostril (intranasal) twice daily (morning and evening) for seven days. Subjects are to pinch the nose to spread the cream.
Study: NCT01969656

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2MD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2MD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2MD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2MD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2MD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcitriol

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT06036875

Intervention type: OTHER
Intervention: Non-Interventional Study
Description: Non-interventional study
Study: NCT04516252

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: BodyWorks Intervention
Description: BodyWorks (BW), a Comprehensive Behavioral Family Lifestyle Interventions (CBFLI), a national, empirically validated, curriculum-based 7-week program will be implemented (Borden et al., 2012; DHHS, 2013)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BodyWorks Intervention
Description: BodyWorks (BW), a Comprehensive Behavioral Family Lifestyle Interventions (CBFLI), a national, empirically validated, curriculum-based 7-week program will be implemented (Borden et al., 2012; DHHS, 2013)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Canine Curriculum
Description: Using our team's expertise in veterinary medicine, human-animal interaction, and animal behavior modification, develop an empirically-based, 7-week module on canine health and behavior.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Ecological Momentary Assessment
Description: Ecological Momentary Assessments (EMA) of physical activity will be conducted using mobile phones for 7 weeks of the BW program, prospectively collecting data on 4 days per week (Saturday to Tuesday) (Dunton et al., 2011; Liao et al., 2016).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ecological Momentary Assessment
Description: Ecological Momentary Assessments (EMA) of physical activity will be conducted using mobile phones for 7 weeks of the BW program, prospectively collecting data on 4 days per week (Saturday to Tuesday) (Dunton et al., 2011; Liao et al., 2016).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical Activity Trackers
Description: Three types of consumer-grade wireless personal activity trackers (PATs): FitBit Inspire® designed for children 8 years of age and older; FitBit Inspire® for adults (Diaz et al., 2015; Espinoza et al., 2017); and FitBark®, wireless, global positioning systems (GPS)-based personal activity trackers for dogs (Patel et al., 2017). This approach will allow us to evaluate quantity (number of steps) and intensity of physical activity in the adolescents, their parents, and their dogs, as well as to synchronize Fitbit Ace and FitBark to establish the amount of shared physical activity of adolescents and their dogs.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity Trackers
Description: Three types of consumer-grade wireless personal activity trackers (PATs): FitBit Inspire® designed for children 8 years of age and older; FitBit Inspire® for adults (Diaz et al., 2015; Espinoza et al., 2017); and FitBark®, wireless, global positioning systems (GPS)-based personal activity trackers for dogs (Patel et al., 2017). This approach will allow us to evaluate quantity (number of steps) and intensity of physical activity in the adolescents, their parents, and their dogs, as well as to synchronize Fitbit Ace and FitBark to establish the amount of shared physical activity of adolescents and their dogs.
Study: NCT05286801

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tiragolumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tiragolumab
Description: Given IV
Study: NCT06460350

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NEUROCUPLE™ Patch
Description: nCAP Medical has developed an effective, safe, non-opioid alternative, the NEUROCUPLE™ device, based on an innovative nanotechnology to reduce surgical pain and facilitate functional recovery while reducing opioid prescriptions, opioid-related adverse events and reducing the cost of care in millions of Americans undergoing TKA each year.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Patch
Description: The placebo patch is identical to the active patch but with no active agents.
Study: NCT06301854

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPN171H
Description: 10 mg/ time, as needed, it is recommended to take warm water within 0.5 to 4 hours before sexual activity.
Study: NCT05113940

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07258669
Description: PF-07258669 will be administered as tablets; every 8 hour (Q8H) or every 12 hour (Q12H) over 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07258669
Description: PF-07258669 will be administered as tablets; every 8 hour (Q8H) or every 12 hour (Q12H) over 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07258669
Description: PF-07258669 will be administered as tablets; every 8 hour (Q8H) or every 12 hour (Q12H) over 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07258669
Description: PF-07258669 will be administered as tablets; every 8 hour (Q8H) or every 12 hour (Q12H) over 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07258669
Description: PF-07258669 will be administered as tablets; every 8 hour (Q8H) or every 12 hour (Q12H) over 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07258669
Description: PF-07258669 will be administered as tablets; every 8 hour (Q8H) or every 12 hour (Q12H) over 14 days
Study: NCT05286801

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: X-Ray Imaging
Description: Undergo x-rays

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: X-Ray Imaging
Description: Undergo x-rays
Study: NCT06634459

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Reia System
Description: Reia pessary
Study: NCT04932447

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Inspiratory Muscle Strength Training
Description: 30 breaths/ day, 5 days/week for 24 weeks.
Study: NCT05113940

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07258669
Description: PF-07258669 will be administered as tablets; every 8 hour (Q8H) or every 12 hour (Q12H) over 14 days
Study: NCT06176534

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental: chemotheyapy
Description: nab-paclitaxel 130mg/m2，day 1 and day 8 + Capecitabine 2000mg/m2, followed by nab-paclitaxel 130mg/m2，day 1 and day 8 or Capecitabine from day1 to DAY 14 Vinorelbine 25mg/m2，day 1 and day 8 + Capecitabine 2000mg/m2，from day1 to DAY 14

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator: endocrine therapy
Description: palbociclib 125mg per day for 21days Dalpiciclib 150mg per day for 21days Letrozole 2.5mg per day Anastrozole 1mg per day fulvestrant 500mg per 28 days
Study: NCT06356103

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Whey-Based Partially Hydrolyzed Formula
Description: Peptamen junior, 100 kcal/100 ml (Nestlé Health Science, Vevey, Switzerland).

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: received 50% of their caloric requirements as isocaloric polymeric formula (standard ) and 50% standard nutritional feeding according to ESPGHAN guidelines
Description: protein and micronutrient requirements according to the recommended dietary allowance (RDA)
Study: NCT06498700

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketamine
Description: 0.5 mg/kg/h ketamine infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexmedetomidine
Description: 0.1 ug/kg/h dexmedetomidine infusion
Study: NCT05726669

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-help materials for depression
Description: Self-help materials for depression based on cognitive behavioural therapy have been created and tailored to those with PH by researchers involved in this project, using the evidence base and theory plus clinical experience. The Medical Research Council Frameworks for complex interventions (Craig et al., 2008; Skivington et al., 2021) have been followed as well as the quality appraisal tool for self-help interventions in depression (Cape, 2015). The self-help materials will be shared for feedback with a readership panel of people with PH and caregivers who are members of Pulmonary Hypertension Association UK (a charity for people with PH) prior to being given to participants. The self-help materials will be provided online or posted in paper form to the intervention group and will take four weeks for the person to complete at home (one booklet per week).
Study: NCT05569629

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bronchial washing before endobronchial biopsy and brushing
Description: Bronchial washing: adding bronchial washing once to the standard endoscopic sampling sequence (endobronchial biopsy and brushing first, followed by bronchial washing once) in the experimental arm
Study: NCT06177418

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transumbilical laparoscopic appendectomy + Glove finger technique
Description: Ssince the appendix becomes infected when it is removed from the umbilicus, the infected appendix contacts the edge of the incision during release, thus contaminating the incision and causing postoperative wound infection. Additionally, in the experimental, to prevent this wound infection, after the appendix is taken out through the umbilical incision, the appendix is placed inside the glove finger, thus preventing the appendix from touching the wound during its release. This reduces wound infection in the postoperative period.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard transumbilical laparoscopic appendectomy
Description: Standart transumbilical laparoscopic appendectomy
Study: NCT02317263

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: testosterone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo gel
Study: NCT05806957

Intervention type: DEVICE
Intervention: Fundus Photography
Description: Subjects will undergo Fundus Photography using FDA approved non-mydriatic fundus cameras and mydriatic camera with OCT